PRESS RELEASE published on 02/21/2025 at 07:30, 1 year 8 months ago Inside Information / Other news releases Sensorion receives positive recommendation from Data Monitoring Committee for Audiogene Phase 1/2 clinical trial of SENS-501 gene therapy program to treat congenital deafness linked to OTOF gene mutations Gene Therapy Sensorion Audiogene Deafness Data Monitoring Committee
BRIEF published on 02/20/2025 at 07:35, 1 year 8 months ago Sensorion to Participate in March Investor Conferences Biotechnology Investor Conferences Sensorion Hearing Loss Therapies March 2025
PRESS RELEASE published on 02/20/2025 at 07:30, 1 year 8 months ago Inside Information / Other news releases Sensorion announces participation in investor conferences in March. CEO and CFO will attend Cowen and Leerink events to present company updates and meet investors Biotechnology CFO Investor Conferences CEO Sensorion
BRIEF published on 02/18/2025 at 07:35, 1 year 8 months ago Sensorion announces its participation in congresses in March 2025 Biotechnology Sensorion Hearing Therapies Medical Innovations Congress 2025
PRESS RELEASE published on 02/18/2025 at 07:30, 1 year 8 months ago Inside Information / Other news releases Sensorion announces participation in upcoming congresses in March to present on innovative biologics and manufacturing challenges for hearing loss disorders Sensorion Hearing Loss Biologics Congresses Manufacturing Challenges
BRIEF published on 02/12/2025 at 11:35, 1 year 8 months ago Sensorion to Participate in ARO 48th Annual Midwinter Meeting Sensorion Hearing Loss ARO Meeting GJB2-GT Therapy Biotech Conference
PRESS RELEASE published on 02/12/2025 at 11:30, 1 year 8 months ago Inside Information / Other news releases Sensorion announces participation in ARO 48th Annual Midwinter Meeting with focus on gene therapy for deafness. Details of presentations by Sensorion executives included Gene Therapy Sensorion ARO Meeting Deafness Sensorion Executives
BRIEF published on 12/27/2024 at 07:35, 1 year 10 months ago Sensorion Completes Enrollment for Audiogene Phase 1/2 Trial Gene Therapy Sensorion Hearing Loss SENS-501 Audiogene Trial
PRESS RELEASE published on 12/27/2024 at 07:30, 1 year 10 months ago Inside Information / Other news releases Sensorion completes enrollment of the first cohort in the Audiogene Phase 1/2 gene therapy clinical trial, targeting infants with hearing loss disorders Gene Therapy Clinical Trial Sensorion Hearing Loss Disorders Audiogene
BRIEF published on 12/18/2024 at 07:35, 1 year 10 months ago Sensorion Reports Positive Preliminary Results for SENS-501 Gene Therapy Clinical Trial SENS-501 Congenital Deafness Biotechnological Innovation
Published on 11/02/2026 at 16:15, 31 minutes ago ACCESS Newswire Launches SPOT, Seven AI Agents That Check Every Press Release Before Submission
Published on 11/02/2026 at 15:00, 1 hour 46 minutes ago CSO of Napo Pharmaceuticals, a Jaguar Health Family Company, and Clinical Investigators Evaluating Crofelemer Conduct Panel Discussion at Pediatric Gastroenterology Conference in Dubai (UAE)
Published on 11/02/2026 at 14:00, 2 hours 46 minutes ago GameSquare to Report Q3 2026 Financial Results on November 16, 2026
Published on 11/02/2026 at 14:00, 2 hours 46 minutes ago Tectonic Metals Intersects 5.61 g/t Au Over 41.15 m, Including 12.94 g/t Au Over 13.72 m, Within 2.86 g/t Au Over 91.44 m, Strengthening Evidence for a Second Gold System at the Flat Gold Project
Published on 11/02/2026 at 13:30, 3 hours 16 minutes ago Electric Metals (USA) Limited Announces Results of Annual Meeting of Stockholders
Published on 11/02/2026 at 15:58, 48 minutes ago Original-Research: Deutsche Rohstoff AG (von First Berlin Equity Research GmbH): Buy
Published on 11/02/2026 at 15:19, 1 hour 26 minutes ago Form 8.3 - The Vanguard Group, Inc.: Prologis, Inc.
Published on 11/02/2026 at 15:19, 1 hour 27 minutes ago Form 8.3 - The Vanguard Group, Inc.: RHI Magnesita N.V.
Published on 11/02/2026 at 15:25, 1 hour 20 minutes ago Guillemot Corporation S.A. | Information regarding the total number of voting rights and shares 31/10/2026
Published on 10/30/2026 at 23:00, 2 days 17 hours ago BIOPHYTIS REPORTS FIRST- HALF 2026 RESULTS AND PROVIDES AN UPDATE ON ITS STRATEGY
Published on 10/30/2026 at 18:00, 2 days 22 hours ago 2026 half-year earnings & third quarter revenue
Published on 10/30/2026 at 12:00, 3 days 4 hours ago Capital increase through exercise of subscription rights
